These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15089044)

  • 41. Extraction Optimization and Structural and Thermal Characterization of the Antimicrobial Abietane 7α-Acetoxy-6β-hydroxyroyleanone.
    Bernardes CES; Garcia C; Pereira F; Mota J; Pereira P; Cebola MJ; Reis CP; Correia I; Piedade MFM; Minas da Piedade ME; Rijo P
    Mol Pharm; 2018 Apr; 15(4):1412-1419. PubMed ID: 29494159
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recrystallization of fluconazole using the supercritical antisolvent (SAS) process.
    Park HJ; Kim MS; Lee S; Kim JS; Woo JS; Park JS; Hwang SJ
    Int J Pharm; 2007 Jan; 328(2):152-60. PubMed ID: 16959448
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Improving Dissolution Properties by Polymers and Surfactants: A Case Study of Celastrol.
    Zha J; Zhang Q; Li M; Wang JR; Mei X
    J Pharm Sci; 2018 Nov; 107(11):2860-2868. PubMed ID: 30017890
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of moisture on the physical stability of polymorphic olanzapine.
    Paisana MC; Wahl MA; Pinto JF
    Int J Pharm; 2016 Jul; 509(1-2):135-148. PubMed ID: 27234701
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characterization of solvatomorphs of methotrexate using thermoanalytical and other techniques.
    Chadha R; Arora P; Kaur R; Saini A; Singla ML; Jain DS
    Acta Pharm; 2009 Sep; 59(3):245-57. PubMed ID: 19819822
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Solid state of a new PDE-5 inhibitor DA-8159: characterization, dissolution, transformation.
    Ryu JY; Sohn YT
    Arch Pharm Res; 2012 May; 35(5):861-6. PubMed ID: 22644853
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Crystal modifications and dissolution rate of piroxicam.
    Lyn LY; Sze HW; Rajendran A; Adinarayana G; Dua K; Garg S
    Acta Pharm; 2011 Dec; 61(4):391-402. PubMed ID: 22202198
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Polymorphism of shikimic acid].
    Wang FF; Yang DZ; Lv Y
    Zhongguo Zhong Yao Za Zhi; 2016 Aug; 41(15):2861-2863. PubMed ID: 28914029
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reevaluation of solubility of tolbutamide and polymorphic transformation from Form I to unknown crystal form.
    Hasegawa G; Komasaka T; Bando R; Yoshihashi Y; Yonemochi E; Fujii K; Uekusa H; Terada K
    Int J Pharm; 2009 Mar; 369(1-2):12-8. PubMed ID: 19026732
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
    Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Solid state characterization of azelnidipine-oxalic acid co-crystal and co-amorphous complexes: The effect of different azelnidipine polymorphs.
    Pan Y; Pang W; Lv J; Wang J; Yang C; Guo W
    J Pharm Biomed Anal; 2017 May; 138():302-315. PubMed ID: 28237872
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Polymorph screening of an active material.
    Láng P; Kiss V; Ambrus R; Farkas G; Szabó-Révész P; Aigner Z; Várkonyi E
    J Pharm Biomed Anal; 2013 Oct; 84():177-83. PubMed ID: 23845379
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Solid state investigation and characterization of the polymorphic and pseudopolymorphic forms of indapamide.
    Ghugare P; Dongre V; Karmuse P; Rana R; Singh D; Kumar A; Filmwala Z
    J Pharm Biomed Anal; 2010 Feb; 51(3):532-40. PubMed ID: 19796901
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Crystal modification of dipyridamole using different solvents and crystallization conditions.
    Adhiyaman R; Basu SK
    Int J Pharm; 2006 Sep; 321(1-2):27-34. PubMed ID: 16842943
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characterization and Stability of Amorphous Tadalafil and Four Crystalline Polymorphs.
    Wei Y; Ling Y; Su M; Qin L; Zhang J; Gao Y; Qian S
    Chem Pharm Bull (Tokyo); 2018; 66(12):1114-1121. PubMed ID: 30504628
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation and correlation of the physicochemical properties of carvedilol.
    Alves JM; Prado LD; Rocha HV
    Pharm Dev Technol; 2016 Nov; 21(7):856-866. PubMed ID: 26336079
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of the solid-dispersion method on the solubility and crystalline property of tacrolimus.
    Joe JH; Lee WM; Park YJ; Joe KH; Oh DH; Seo YG; Woo JS; Yong CS; Choi HG
    Int J Pharm; 2010 Aug; 395(1-2):161-6. PubMed ID: 20580799
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Can crystal engineering be as beneficial as micronisation and overcome its pitfalls?: A case study with cilostazol.
    Sai Gouthami K; Kumar D; Thipparaboina R; Chavan RB; Shastri NR
    Int J Pharm; 2015 Aug; 491(1-2):26-34. PubMed ID: 26068197
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characterization of tolbutamide polymorphs (Burger's forms II and IV) and polymorphic transition behavior.
    Kimura K; Hirayama F; Uekama K
    J Pharm Sci; 1999 Apr; 88(4):385-91. PubMed ID: 10187747
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Physical characterization of solid iopanoic acid forms.
    Stagner WC; Guillory JK
    J Pharm Sci; 1979 Aug; 68(8):1005-9. PubMed ID: 480153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.